Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

NCT04440345 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and side effects of the drug IBI362 in adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 60 people

Who can join Ages 18–75 · all sexes

Timeline Started 2020-06 · est. completion 2021-08

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04440345 ↗

Description as written by the study sponsor.

This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Overweight or Obese Male and Female Subjects.

Treatments tested

IBI362 Drug

Administered by subcutaneous injection
Placebo Drug

Administered by subcutaneous injection

Main thing measured	Number of treatment adverse events
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Overweight or Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04440345 ↗